Sunlight New Yao-B (01952) rose more than 4%, as of press time, up 4.23%, reporting HKD 20.45, turnover of HKD 15.7881 million.
Zhixin Finance App learned that Sunlight New Yao-B (01952) rose more than 4%, as of press time, up 4.23%, reporting HKD 20.45, turnover of HKD 15.7881 million.
On the news front, Sunlight New Yao recently announced that the National Medical Products Administration has officially accepted the company's supplemental application for the final clinical trial stage complete data of NEFECON. After the approval of the supplemental application, NEFECON will become the first and only drug for treating IgA nephropathy with a complete approval from the National Medical Products Administration in China. China International Capital Corporation previously pointed out that IgA nephropathy has a high potential market space, but the growth of product revenue requires active commercial strategies. It is recommended to pay attention to the trend of NEFECON's revenue surge in 2024.
In addition, the company announced today that the global phase 2B PALIZADE trial of zetomipzomib (zetozomib) for the treatment of active lupus nephritis (LN) being promoted in China has completed the first patient's medication. Zetomipzomib is a new and unique selective immunoproteasome inhibitor used to treat a range of autoimmune diseases, including lupus nephritis, systemic lupus erythematosus (SLE), and autoimmune hepatitis.